Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Return on Assets (2018 - 2020)

Historic Return on Assets for Monopar Therapeutics (MNPR) over the last 3 years, with Q3 2020 value amounting to 0.08%.

  • Monopar Therapeutics' Return on Assets rose 6700.0% to 0.08% in Q3 2020 from the same period last year, while for Sep 2020 it was 0.08%, marking a year-over-year increase of 6700.0%. This contributed to the annual value of 0.42% for FY2019, which is 400.0% down from last year.
  • Monopar Therapeutics' Return on Assets amounted to 0.08% in Q3 2020, which was up 6700.0% from 0.15% recorded in Q2 2020.
  • Over the past 5 years, Monopar Therapeutics' Return on Assets peaked at 0.08% during Q3 2020, and registered a low of 1.96% during Q2 2018.
  • In the last 3 years, Monopar Therapeutics' Return on Assets had a median value of 0.47% in 2019 and averaged 0.67%.
  • The largest annual percentage gain for Monopar Therapeutics' Return on Assets in the last 5 years was 13000bps (2019), contrasted with its biggest fall of -3900bps (2019).
  • Quarter analysis of 3 years shows Monopar Therapeutics' Return on Assets stood at 0.42% in 2018, then decreased by -13bps to 0.47% in 2019, then soared by 83bps to 0.08% in 2020.
  • Its Return on Assets was 0.08% in Q3 2020, compared to 0.15% in Q2 2020 and 0.22% in Q1 2020.